litlas
ログインアカウント作成

Hervé Tilly

1983–2025 年に発表

192
論文数
40,672
被引用数
105
h 指数
188
i10 指数

被引用数

Hervé Tilly の年別被引用数1983 年: 被引用 1 件1984 年: 被引用 5 件1985 年: 被引用 3 件1986 年: 被引用 5 件1987 年: 被引用 3 件1988 年: 被引用 2 件1990 年: 被引用 3 件1991 年: 被引用 6 件1992 年: 被引用 7 件1993 年: 被引用 12 件1994 年: 被引用 30 件1995 年: 被引用 38 件1996 年: 被引用 23 件1997 年: 被引用 49 件1998 年: 被引用 54 件1999 年: 被引用 55 件2000 年: 被引用 80 件2001 年: 被引用 50 件2002 年: 被引用 82 件2003 年: 被引用 145 件2004 年: 被引用 101 件2005 年: 被引用 132 件2006 年: 被引用 152 件2007 年: 被引用 191 件2008 年: 被引用 218 件2009 年: 被引用 139 件2010 年: 被引用 195 件2011 年: 被引用 256 件2012 年: 被引用 244 件2013 年: 被引用 252 件2014 年: 被引用 280 件2015 年: 被引用 296 件2016 年: 被引用 294 件2017 年: 被引用 297 件2018 年: 被引用 286 件2019 年: 被引用 981 件2020 年: 被引用 1,108 件2021 年: 被引用 1,087 件2022 年: 被引用 872 件2023 年: 被引用 571 件2024 年: 被引用 1,055 件2025 年: 被引用 491 件2026 年: 被引用 5 件1989 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,768 件、この内訳の 24%フランス: 引用元論文 950 件、この内訳の 8.2%中国: 引用元論文 777 件、この内訳の 6.7%ドイツ: 引用元論文 754 件、この内訳の 6.5%イギリス: 引用元論文 744 件、この内訳の 6.4%イタリア: 引用元論文 711 件、この内訳の 6.2%カナダ: 引用元論文 473 件、この内訳の 4.1%スペイン: 引用元論文 450 件、この内訳の 3.9%スイス: 引用元論文 407 件、この内訳の 3.5%日本: 引用元論文 365 件、この内訳の 3.2%オランダ: 引用元論文 340 件、この内訳の 3%オーストラリア: 引用元論文 301 件、この内訳の 2.6%
0%24%その他 21.7%

機関

分野

  • Medicine81.5%
  • Biochemistry, Genetics and Molecular Biology13.3%
  • Immunology and Microbiology3.9%
  • Computer Science0.3%
  • Materials Science0.2%
  • Mathematics0.1%
  • その他0.7%

トピック

  • Lymphoma Diagnosis and Treatment20.3%
  • CAR-T cell therapy research6.4%
  • Chronic Lymphocytic Leukemia Research5.8%
  • CNS Lymphoma Diagnosis and Treatment5.5%
  • Viral-associated cancers and disorders4.9%
  • Cutaneous lymphoproliferative disorders research2.9%
  • その他54.2%

共著者

全論文

検索で開く
  1. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

    著者: Hervé Tilly, Franck Morschhauser, Laurie H. Sehn, Jonathan W. Friedberg, Marek Trněný, Jeff P. Sharman, Charles Herbaux, John M. Burke, Matthew Matasar, Shinya Rai, Koji Izutsu, Neha Mehta-Shah, Lucie Oberic, Adrien Chauchet, Wojciech Jurczak, Yuqin Song, Richard Greil, Larysa Mykhalska, Juan M. Bergua-Burgués, Matthew C. Cheung, Antonio Pinto, Ho-Jin Shin, Greg Hapgood, Eduardo Munhoz, Pau Abrisqueta, Jyh-Pyng Gau, Jamie Hirata, Yanwen Jiang, Mark Yan, Calvin Lee, Christopher R. Flowers, Gilles Salles - New England Journal of Medicine 2021 被引用: 843

  2. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

    著者: Bertrand Coiffier, Éric Lepage, Josette Brière, Raoul Herbrecht, Hervé Tilly, Réda Bouabdallah, Pierre Morel, Éric Van Den Neste, Gilles Salles, Philippe Gaulard, Félix Reyes, P Lederlin, Christian Gisselbrecht - New England Journal of Medicine 2002 被引用: 5,562

  3. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

    著者: Franck Morschhauser, Hervé Tilly, Aristeidis Chaidos, Pam McKay, Tycel Phillips, Sarit Assouline, Connie Lee Batlevi, Phillip L. Campbell, Vincent Ribrag, Gandhi Damaj, Michael Dickinson, Wojciech Jurczak, Maciej Kazmierczak, Stephen Opat, John Radford, Anna Schmitt, Jay Yang, Jennifer Whalen, Shefali Agarwal, Deyaa Adib, Gilles Salles - The Lancet Oncology 2020 被引用: 587

  4. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

    著者: Bertrand Coiffier, Catherine Thiéblemont, Éric Van Den Neste, G. Lepeu, Isabelle Plantier, Sylvie Castaigné, Sophie Lefort, Gérald Marit, Margaret Macro, Catherine Sebban, Karim Belhadj, Dominique Bordessoule, Christophe Fermé, Hervé Tilly - Blood 2010 被引用: 1,558

  5. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI

    著者: Amy S. Ruppert, Jesse G. Dixon, Gilles Salles, Anna Wall, David Cunningham, Viola Poeschel, Corinne Haïoun, Hervé Tilly, Hervé Ghesquières, Marita Ziepert, Jocelyne Flament, Christopher R. Flowers, Qian Shi, Norbert Schmitz - Blood 2020 被引用: 378

  6. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    著者: Hervé Tilly, María Gomes da Silva, Umberto Vitolo, Andrew Jack, Michel Meignan, Armando López‐Guillermo, Jan Walewski, M. André, Peter Johnson, Michael Pfreundschuh, Marco Ladetto - Annals of Oncology 2015 被引用: 925

  7. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

    著者: Kim Linton, Umberto Vitolo, Wojciech Jurczak, Pieternella J. Lugtenburg, Emmanuel Gyan, Anna Sureda, Jacob Haaber Christensen, Brian Hess, Hervé Tilly, Raúl Córdoba, David Lewis, Craig Okada, Martin Hutchings, Michael Roost Clausen, Juan‐Manuel Sancho, Tara Cochrane, Sirpa Leppä, Martine E.D. Chamuleau, Diana Gernhardt, Işıl Altıntaş, Yan Liu, Tahamtan Ahmadi, Minh H. Dinh, Daniela Hoehn, Elena Favaro, Brian Elliott, Catherine Thiéblemont, Julie M. Vose - The Lancet Haematology 2024 被引用: 139

  8. Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

    著者: Matthew J. Maurer, Hervé Ghesquières, Jean‐Philippe Jais, Thomas E. Witzig, Corinne Haïoun, Carrie A. Thompson, Richard Delarue, Ivana N. Micallef, Frédéric Peyrade, William R. Macon, Thierry Jo Molina, Nicolas Ketterer, Sergei Syrbu, Olivier Fitoussi, Paul J. Kurtin, Cristine Allmer, Emmanuelle Nicolas‐Virelizier, Susan L. Slager, Thomas M. Habermann, Brian K. Link, Gilles Salles, Hervé Tilly, James R. Cerhan - Journal of Clinical Oncology 2014 被引用: 410

  9. Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

    著者: Maria Corinna Palanca-Wessels, Myron S. Czuczman, Gilles Salles, Sarit Assouline, Laurie H. Sehn, Ian W. Flinn, Manish R. Patel, Randeep Sangha, Anton Hagenbeek, Ranjana H. Advani, Hervé Tilly, Olivier Casasnovas, Oliver W. Press, Sreeni Yalamanchili, Robert S. Kahn, Randall Dere, Dan Lü, Surai Jones, Cheryl Jones, Yu-Waye Chu, Franck Morschhauser - The Lancet Oncology 2015 被引用: 335

  10. TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis

    著者: Cyril Quivoron, Lucile Couronné, Véronique Della Valle, Cécile K. Lopez, Isabelle Plo, Orianne Wagner‐Ballon, Marcio Do Cruzeiro, François Delhommeau, Bertrand Arnulf, Marc‐Henri Stern, Lucy A. Godley, Paule Opolon, Hervé Tilly, Éric Solary, Yannis Duffourd, Philippe Dessen, Hélène Merle‐Béral, Florence Nguyen‐Khac, Michaëla Fontenay, William Vainchenker, Christian Bastard, Thomas Mercher, Olivier Bernard - Cancer Cell 2011 被引用: 897

  11. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

    著者: Franck Morschhauser, Ian W. Flinn, Ranjana H. Advani, Laurie H. Sehn, Catherine Diefenbach, Kathryn S. Kolibaba, Oliver W. Press, Gilles Salles, Hervé Tilly, Andy I. Chen, Sarit Assouline, Bruce D. Cheson, Martin Dreyling, Anton Hagenbeek, Pier Luigi Zinzani, Surai Jones, Ji Cheng, Dan Lü, Elicia Penuel, Jamie Hirata, Michael Wenger, Yu-Waye Chu, Jeff P. Sharman - The Lancet Haematology 2019 被引用: 249

  12. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

    著者: Franck Morschhauser, Nathan Fowler, Pierre Feugier, Réda Bouabdallah, Hervé Tilly, M. Lia Palomba, Christophe Fruchart, Edward N. Libby, Olivier Casasnovas, Ian W. Flinn, Corinne Haïoun, Hervé Maisonneuve, Loïc Ysebaert, Nancy L. Bartlett, Kamal Bouabdallah, Pauline Brice, Vincent Ribrag, Nicolas Daguindau, Steven Le Gouill, Gian M. Pica, Alejandro Martı́n, Armando López‐Guillermo, Jean-François Larouche, Kiyoshi Ando, María Gomes da Silva, Marc André, Pierre Zachée, Laurie H. Sehn, Kensei Tobinai, Guillaume Cartron, David Liu, Jianming Wang, Luc Xerri, Gilles Salles - New England Journal of Medicine 2018 被引用: 362

  13. Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

    著者: Emmanuel Bachy, John F. Seymour, Pierre Feugier, Fritz Offner, Armando López‐Guillermo, David Belada, Luc Xerri, John Catalano, Pauline Brice, François Lemonnier, Alejandro Martı́n, Olivier Casasnovas, Lars Møller Pedersen, Véronique Dorvaux, David Simpson, Sirpa Leppä, Jean Gabarre, María Gomes da Silva, Sylvie Glaisner, Loïc Ysebaert, Anne Vekhoff, Tanin Intragumtornchai, Steven Le Gouill, Andrew Lister, Jane Estell, Giuseppe Milone, Anne Sonet, Jonathan Farhi, Harald Zeuner, Hervé Tilly, Gilles Salles - Journal of Clinical Oncology 2019 被引用: 278

  14. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

    著者: Pier Luigi Zinzani, Jiřı́ Mayer, Christopher R. Flowers, Fontanet Bijou, Ana Carla Oliveira, Yuqin Song, Qingyuan Zhang, Michele Merli, Krimo Bouabdallah, Peter Ganly, Huilai Zhang, Roderick J. Johnson, Alejandro Martı́n, Mariano Provencio, Marek Trněný, Sam Yuen, Hervé Tilly, Edwin Kingsley, Gayane Tumyan, Sarit Assouline, Rebecca Auer, Elena V. Ivanova, Pil Kim, Sha Huang, Richard Delarue, Judith Trotman - Journal of Clinical Oncology 2023 被引用: 98

  15. Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte

    著者: Pierre Feugier, Ambro van Hoof, Catherine Sebban, P. Solal-Céligny, Réda Bouabdallah, Christophe Fermé, B. Christian, Éric Lepage, Hervé Tilly, Franck Morschhauser, Philippe Gaulard, Gilles Salles, André Bosly, Christian Gisselbrecht, F Reyes, Bertrand Coiffier - Journal of Clinical Oncology 2005 被引用: 1,499

  16. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.

    著者: Pauline Brice, Y Bastion, Éric Lepage, Nicole Brousse, Corinne Haïoun, Philippe Moreau, Nicole Straetmans, Hervé Tilly, I Tabah, Philippe Solal‐Céligny - Journal of Clinical Oncology 1997 被引用: 641

  17. High total metabolic tumor volume at baseline predicts survival independent of response to therapy

    著者: Laëtitia Vercellino, Anne‐Ségolène Cottereau, Olivier Casasnovas, Hervé Tilly, Pierre Feugier, Loïc Chartier, Christophe Fruchart, Louise Roulin, Lucie Obéric, Gian Matteo Pica, Vincent Ribrag, Julie Abraham, Marc A. Simon, Hugo González, Réda Bouabdallah, Olivier Fitoussi, Catherine Sebban, Armando López‐Guillermo, Laurence Sanhès, Franck Morschhauser, Judith Trotman, Bernadette Corront, Bachra Choufi, Sylvia Snauwaert, Pascal Godmer, Josette Brière, Gilles Salles, Philippe Gaulard, Michel Meignan, Catherine Thiéblemont - Blood 2020 被引用: 185

  18. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

    著者: Franck Morschhauser, Loretta J. Nastoupil, Pierre Feugier, Jean‐Marc Schiano de Colella, Hervé Tilly, Maria Lia Palomba, Emmanuel Bachy, Christophe Fruchart, Edward N. Libby, Olivier Casasnovas, Ian W. Flinn, Corinne Haïoun, Hervé Maisonneuve, Loïc Ysebaert, Nancy L. Bartlett, Kamal Bouabdallah, Pauline Brice, Vincent Ribrag, Steven Le Gouill, Nicolas Daguindau, Stéphanie Guidez, Gian Matteo Pica, Alejandro Martı́n, Armondo López-Guillermo, Jean-François Larouche, Kiyoshi Ando, María Gomes da Silva, Marc André, Wu Kalung, Laurie H. Sehn, Koji Izutsu, Guillaume Cartron, Argyrios Gkasiamis, Russell Crowe, Luc Xerri, Nathan Fowler, Gilles Salles - Journal of Clinical Oncology 2022 被引用: 68

  19. A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

    著者: Krish Patel, Peter A. Riedell, Hervé Tilly, Sairah Ahmed, Jean‐Marie Michot, Hervé Ghesquières, Jean Marc Schiano de Collela, Asher Chanan‐Khan, Kamal Bouabdallah, Benoît Tessoulin, Sunil Iyengar, Meixiao Long, Raphael Clynes, Jitendra Kanodia, Lei Bao, Ying Ding, Jianhua Jin, William B. Ainsworth, Raman Garcha, Steve Kye, Tycel Phillips - Blood 2022 被引用: 38

  20. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

    著者: Frédéric Peyrade, Fabrice Jardin, Catherine Thiéblemont, Antoine Thyss, Jean‐François Emile, Sylvie Castaigné, Bertrand Coiffier, Corinne Haïoun, Serge Bologna, Olivier Fitoussi, G. Lepeu, Christophe Fruchart, Dominique Bordessoule, Michel Blanc, Richard Delarue, Maud Janvier, Bruno César Corrêa Salles, Marc André, Marion Fournier, Philippe Gaulard, Hervé Tilly - The Lancet Oncology 2011 被引用: 545

  21. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts

    著者: Sarah Huet, Bruno Tesson, Jean‐Philippe Jais, Andrew L. Feldman, Laura Magnano, Emilie Thomas, Alexandra Traverse‐Glehen, Benoît Albaud, Marjorie Carrère, Luc Xerri, Stephen M. Ansell, Lucile Baseggio, Cécile Réyès, Karin Tarte, Sandrine Boyault, Corinne Haïoun, Brian K. Link, Pierre Feugier, Armando López‐Guillermo, Hervé Tilly, Pauline Brice, Sandrine Hayette, Fabrice Jardin, Fritz Offner, Pierre Sujobert, David Gentien, Alain Viari, Elı́as Campo, James R. Cerhan, Gilles Salles - The Lancet Oncology 2018 被引用: 220

  22. Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study

    著者: Vincent Camus, Mathieu Viennot, Justine Lequesne, Pierre‐Julien Viailly, Élodie Bohers, Lucile Bessi, B. Marcq, Pascaline Etancelin, Sydney Dubois, Jean‐Michel Picquenot, Elena‐Liana Veresezan, Marie Cornic, Lucie Burel, Justine Loret, Stéphanie Becker, Pierre Decazes, Pascal Lenain, Stéphane Leprêtre, Émilie Lemasle, Hélène Lanic, Anne‐Lise Ménard, Nathalie Contentin, Hervé Tilly, Aspasia Stamatoullas, Fabrice Jardin - Haematologica 2020 被引用: 106

  23. Baseline Metabolic Tumor Volume Predicts Outcome in High–Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies

    著者: Michel Meignan, Anne‐Ségolène Cottereau, Annibale Versari, Loïc Chartier, Jehan Dupuis, Sami Boussetta, Ilaria Grassi, Olivier Casasnovas, Corinne Haïoun, Hervé Tilly, Vittoria Tarantino, Julien Dubreuil, Massimo Federico, Gilles Salles, Stefano Luminari, Judith Trotman - Journal of Clinical Oncology 2016 被引用: 337

  24. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

    著者: Gilles Salles, John F. Seymour, Fritz Offner, Armando López‐Guillermo, David Belada, Luc Xerri, Pierre Feugier, Réda Bouabdallah, John Catalano, Pauline Brice, Dolores Caballero, Corinne Haïoun, Lars Møller Pedersen, Alain Delmer, David Simpson, Sirpa Leppä, Pierre Soubeyran, Anton Hagenbeek, Olivier Casasnovas, Tanin Intragumtornchai, Christophe Fermé, María Gomes da Silva, Catherine Sebban, Andrew Lister, Jane Estell, Giuseppe Milone, Anne Sonet, Myriam Mendila, Bertrand Coiffier, Hervé Tilly - The Lancet 2010 被引用: 1,066